Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCSK9 | Q8NBP7 | 7/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ACSS2 | Q9NR19 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.34 |
| ▸ | GSR | P00390 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2158193 | 1.00 | PCSK9 (0.46) | PCSK9CYP11B1CYP11B2ALDH1A1SMN1; SMN2 | |
| SCHEMBL2159170 | 0.88 | ALDH1A1 (0.40) | PCSK9ALDH1A1SMN1; SMN2POLBMPO | |
| SCHEMBL2159173 | 0.88 | ALDH1A1 (0.40) | PCSK9ALDH1A1SMN1; SMN2POLBMPO | |
| SCHEMBL2158194 | 0.73 | PCSK9 (0.46) | PCSK9CYP11B1CYP11B2ACSS2POLB | |
| SCHEMBL30621949 | 0.73 | CYP11B1 (0.50) | PCSK9CYP11B1CYP11B2ACSS2POLB | |
| SCHEMBL2857716 | 0.70 | NPC1 (0.46) | PCSK9ALDH1A1POLBMEN1HCRTR1 | |
| SCHEMBL2634929 | 0.69 | SMN1; SMN2 (0.58) | PCSK9CYP11B1CYP11B2SMN1; SMN2ACSS2 | |
| SCHEMBL28463862 | 0.69 | CYP11B1 (0.50) | PCSK9CYP11B1CYP11B2ACSS2MEN1 | |
| SCHEMBL3970030 | 0.69 | CYP11B1 (0.50) | PCSK9CYP11B1CYP11B2ACSS2MEN1 | |
| SCHEMBL1833960 | 0.69 | CYP11B2 (0.47) | PCSK9CYP11B1CYP11B2ACSS2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183974-A1 | 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI (IT) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183974-A1 | 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | SHH, SMO, GLI1 | PCSK9 4731/4885CYP11B1 708/4885CYP11B2 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.